Literature DB >> 22476576

Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction.

Karin Leander1, Margareta Blombäck, Håkan Wallén, Shu He.   

Abstract

We assessed whether abnormality of haemostasis measured by a newly developed global method is associated with risk of a first myocardial infarction (MI). The global markers coagulation activation profile (Cp), fibrinolysis activation profile (Fp) and sum of fibrin optical density over time (Fibrin OD-sum) were determined in plasma from 800 MI cases and 1,123 controls included in the Stockholm Heart Epidemiology Program. Clot lysis time (CLT) was also determined based on raw data of fibrin OD from the global assay. Odds ratios (OR) of MI with 95% confidence intervals (CI) were calculated using logistic regression. A Fp value <10th percentile value in controls was significantly associated with increased MI risk; OR after multivariate adjustments for conventional cardiovascular risk factors 1.66 (95% CI 1.22-2.27). For an abnormally long CLT (>90th percentile value in controls) the adjusted OR of MI was 2.62 (95% CI 1.87-3.66) and for a high Fibrin OD-sum value (>90th percentile in controls) it was 1.86 (95% CI 1.37-2.53). A high Cp value was not significantly associated with MI. In conclusion, we found that abnormal haemostasis in platelet-poor plasma, reflected either as an attenuated fibrinolytic capacity or the resulting increase of fibrin formation, was associated with increased MI risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476576     DOI: 10.1160/TH11-11-0760

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Plasma clot lysis time and its association with cardiovascular risk factors in black Africans.

Authors:  Zelda de Lange; Marlien Pieters; Johann C Jerling; Annamarie Kruger; Dingeman C Rijken
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

Review 2.  Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Authors:  Katherine Kearney; Darren Tomlinson; Kerrie Smith; Ramzi Ajjan
Journal:  Cardiovasc Diabetol       Date:  2017-03-09       Impact factor: 9.951

3.  Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome.

Authors:  Ying X Gue; Rahim Kanji; David M Wellsted; Manivannan Srinivasan; Solange Wyatt; Diana A Gorog
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

4.  Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long-term follow-up study.

Authors:  Agata Hanna Bryk; Małgorzata Konieczyńska; Maciej Polak; Dariusz Plicner; Maciej Bochenek; Anetta Undas
Journal:  Cardiovasc Diabetol       Date:  2021-02-18       Impact factor: 9.951

5.  Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure.

Authors:  Søs Neergaard-Petersen; Ramzi Ajjan; Anne-Mette Hvas; Katharina Hess; Sanne Bøjet Larsen; Steen Dalby Kristensen; Erik Lerkevang Grove
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

6.  Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.

Authors:  Wael Sumaya; Lars Wallentin; Stefan K James; Agneta Siegbahn; Katja Gabrysch; Maria Bertilsson; Anders Himmelmann; Ramzi A Ajjan; Robert F Storey
Journal:  Eur Heart J       Date:  2018-04-01       Impact factor: 29.983

7.  Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study.

Authors:  Wael Sumaya; Lars Wallentin; Stefan K James; Agneta Siegbahn; Katja Gabrysch; Anders Himmelmann; Ramzi A Ajjan; Robert F Storey
Journal:  Thromb Haemost       Date:  2020-01-23       Impact factor: 5.249

8.  Properties of Plasma Clots in Adult Patients Following Fontan Procedure: Relation to Clot Permeability and Lysis Time-Multicenter Study.

Authors:  Maciej Skubera; Aleksandra Gołąb; Dariusz Plicner; Joanna Natorska; Michał Ząbczyk; Olga Trojnarska; Anna Mazurek-Kula; Monika Smaś-Suska; Agnieszka Bartczak-Rutkowska; Piotr Podolec; Lidia Tomkiewicz-Pająk
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.